JPMorgan Chase & Co. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

JPMorgan Chase & Co. lowered its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 73.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,065 shares of the company’s stock after selling 103,426 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.06% of Kymera Therapeutics worth $1,491,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock worth $196,617,000 after purchasing an additional 133,546 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Kymera Therapeutics during the fourth quarter worth $310,000. Teacher Retirement System of Texas grew its stake in Kymera Therapeutics by 35.8% during the fourth quarter. Teacher Retirement System of Texas now owns 11,490 shares of the company’s stock valued at $462,000 after acquiring an additional 3,026 shares in the last quarter. Swiss National Bank increased its holdings in Kymera Therapeutics by 15.6% in the 4th quarter. Swiss National Bank now owns 76,200 shares of the company’s stock valued at $3,066,000 after acquiring an additional 10,300 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its holdings in Kymera Therapeutics by 23.5% in the 4th quarter. E Fund Management Co. Ltd. now owns 67,068 shares of the company’s stock valued at $2,698,000 after acquiring an additional 12,776 shares during the last quarter.

Insiders Place Their Bets

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the sale, the insider now owns 80,085 shares of the company’s stock, valued at $2,438,588.25. The trade was a 2.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,659 shares of company stock worth $324,567 over the last quarter. Company insiders own 15.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on KYMR shares. Leerink Partners restated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. HC Wainwright lifted their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Citigroup initiated coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 target price for the company. Finally, Stephens restated an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Kymera Therapeutics Trading Down 0.9 %

Shares of NASDAQ:KYMR opened at $33.26 on Friday. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -14.21 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27. The firm’s 50-day moving average is $29.89 and its 200 day moving average is $38.61.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. As a group, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.